A Tutorial on Target-Mediated Drug Disposition (TMDD) Models

Target‐mediated drug disposition (TMDD) is the phenomenon in which a drug binds with high affinity to its pharmacological target site (such as a receptor) to such an extent that this affects its pharmacokinetic characteristics. The aim of this Tutorial is to provide an introductory guide to the mathematical aspects of TMDD models for pharmaceutical researchers. Examples of Berkeley Madonna code for some models discussed in this Tutorial are provided in the Supplementary Materials.

• Publication year

  2015

• Venue

  CPT: Pharmacometrics & Systems Pharmacology

• Publication date

  2015-06-01

• Fields of study

  Mathematics, Medicine, Computer Science

• Identifiers
  DOI 10.1002/psp4.41PMID 26225261PMCID 4505827
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacology in Drug Discovery: Understanding Drug Response

  2016cited by this paper
• A mathematical analysis of rebound in a target-mediated drug disposition model: I.Without feedback

  2014cited by this paper
• Visualization and Communication of Pharmacometric Models With Berkeley Madonna

  2014cited by this paper
• Pharmacokinetic and Pharmacodynamic Relationship of AMG 811, An Anti-IFN-γ IgG1 Monoclonal Antibody, in Patients with Systemic Lupus Erythematosus

  2014cited by this paper
• A mathematical analysis of rebound in a target-mediated drug disposition model: II. With feedback

  2014cited by this paper
• Survey of monoclonal antibody disposition in man utilizing a minimal physiologically-based pharmacokinetic model

  2014cited by this paper
• Special Section on DMPK of Therapeutic Proteins—Minireview Pharmacokinetic Modeling of the Subcutaneous Absorption of Therapeutic Proteins

  2014cited by this paper
• Agonistic TAM-163 antibody targeting tyrosine kinase receptor-B

  2013cited by this paper
• Pharmacokinetics, Pharmacodynamics and Physiologically-Based Pharmacokinetic Modelling of Monoclonal Antibodies

  2013cited by this paper
• Factors Influencing Magnitude and Duration of Target Inhibition Following Antibody Therapy: Implications in Drug Discovery and Development

  2013cited by this paper
• Mechanisms of Subcutaneous Absorption of Rituximab in Rats

  2013cited by this paper
• Target-mediated drug disposition and prolonged liver accumulation of a novel humanized anti-CD81 monoclonal antibody in cynomolgus monkeys

  2013cited by this paper
• Interspecies Modeling and Prediction of Human Exenatide Pharmacokinetics

  2013cited by this paper
• Application of Target-Mediated Drug Disposition Model to Small Molecule Heat Shock Protein 90 Inhibitors

  2013cited by this paper
• Population Pharmacokinetic Analysis of Denosumab in Patients with Bone Metastases from Solid Tumours

  2012cited by this paper
• A Model-Based Approach to Predicting the Human Pharmacokinetics of a Monoclonal Antibody Exhibiting Target-Mediated Drug Disposition

  2012cited by this paper
• Methods of solving rapid binding target-mediated drug disposition model for two drugs competing for the same receptor

  2012cited by this paper
• Application of pharmacokinetics-pharmacodynamics/clinical response modeling and simulation for biologics drug development.

  2012cited by this paper
• Mechanism-based population pharmacokinetic modelling in diabetes: vildagliptin as a tight binding inhibitor and substrate of dipeptidyl peptidase IV.

  2012cited by this paper
• Predicting the F(ab)-mediated effect of monoclonal antibodies in vivo by combining cell-level kinetic and pharmacokinetic modelling

  2012cited by this paper
• Dose correction for the Michaelis–Menten approximation of the target-mediated drug disposition model

  2012cited by this paper
• Dynamics of target-mediated drug disposition: characteristic profiles and parameter identification

  2012cited by this paper
• Population Pharmacokinetic and Pharmacodynamic Model‐Based Comparability Assessment of a Recombinant Human Epoetin Alfa and the Biosimilar HX575

  2012cited by this paper
• Target-Mediated Pharmacokinetic and Pharmacodynamic Model of Exendin-4 in Rats, Monkeys, and Humans

  2012cited by this paper
• Linking interleukin-6 receptor blockade with tocilizumab and its hematological effects using a modeling approach

  2012cited by this paper
• Pharmacokinetic and Pharmacodynamic Properties of Canakinumab, a Human Anti-Interleukin-1β Monoclonal Antibody

  2012cited by this paper
• The Utility of Modeling and Simulation Approaches to Evaluate Immunogenicity Effect on the Therapeutic Protein Pharmacokinetics

  2012cited by this paper
• From Target Selection to the Minimum Acceptable Biological Effect Level for Human Study: Use of Mechanism-based PK/PD Modeling to Design Safe and Efficacious Biologics

  2011cited by this paper
• Targeted Drug Delivery by Gemtuzumab Ozogamicin: Mechanism-Based Mathematical Model for Treatment Strategy Improvement and Therapy Individualization

  2011cited by this paper
• Population PK and IgE Pharmacodynamic Analysis of a Fully Human Monoclonal Antibody Against IL4 Receptor

  2011cited by this paper
• Theoretical Analysis of Interplay of Therapeutic Protein Drug and Circulating Soluble Target: Temporal Profiles of ‘Free’ and ‘Total’ Drug and Target

  2011cited by this paper
• Pharmacokinetic and Pharmacodynamic Modeling of Exendin-4 in Type 2 Diabetic Goto-Kakizaki Rats

  2011cited by this paper
• Theoretical Considerations of Target-Mediated Drug Disposition Models: Simplifications and Approximations

  2011cited by this paper
• Impact of dose selection on parameter estimation using a rapid binding approximation model of target-mediated drug disposition

  2011cited by this paper
• A mechanism-based model for the population pharmacokinetics of free and bound aflibercept in healthy subjects.

  2011cited by this paper
• Subcutaneous Absorption of Monoclonal Antibodies: Role of Dose, Site of Injection, and Injection Volume on Rituximab Pharmacokinetics in Rats

  2011cited by this paper
• Mathematical analysis of the pharmacokinetic-pharmacodynamic (PKPD) behaviour of monoclonal antibodies: predicting in vivo potency.

  2011influential reference
• Selection between Michaelis–Menten and target-mediated drug disposition pharmacokinetic models

  2010cited by this paper
• Pharmacodynamics-Mediated Drug Disposition (PDMDD) and Precursor Pool Lifespan Model for Single Dose of Romiplostim in Healthy Subjects

  2010cited by this paper
• Interspecies Scaling of Receptor-Mediated Pharmacokinetics and Pharmacodynamics of Type I Interferons

  2010cited by this paper
• Applying Physiological and Biochemical Concepts to Optimize Biological Drug Development

  2010cited by this paper
• Simultaneous Pharmacokinetics/Pharmacodynamics Modeling of Recombinant Human Erythropoietin upon Multiple Intravenous Dosing in Rats

  2010cited by this paper
• The Application of Target Information and Preclinical Pharmacokinetic/Pharmacodynamic Modeling in Predicting Clinical Doses of a Dickkopf-1 Antibody for Osteoporosis

  2010cited by this paper
• Target-mediated drug disposition model for drugs that bind to more than one target

  2010cited by this paper
• Pharmacokinetics of Anti-hepcidin Monoclonal Antibody Ab 12B9m and Hepcidin in Cynomolgus Monkeys

  2010cited by this paper
• Type I Interferon Receptor is a Primary Regulator of Target-Mediated Drug Disposition of Interferon-β in Mice

  2010cited by this paper
• Properties of a general PK/PD model of antibody-ligand interactions for therapeutic antibodies that bind to soluble endogenous targets

  2010cited by this paper
• On setting the first dose in man: quantitating biotherapeutic drug-target binding through pharmacokinetic and pharmacodynamic models.

  2010cited by this paper
• Impact of Target‐Mediated Drug Disposition on Linagliptin Pharmacokinetics and DPP‐4 Inhibition in Type 2 Diabetic Patients

  2010cited by this paper
• Gaining insights into the consequences of target-mediated drug disposition of monoclonal antibodies using quasi-steady-state approximations

  2009cited by this paper
• Numerical validation and properties of a rapid binding approximation of a target-mediated drug disposition pharmacokinetic model

  2009cited by this paper
• Nonlinear pharmacokinetics of therapeutic proteins resulting from receptor mediated endocytosis

  2009cited by this paper
• Physiologically Based Pharmacokinetic Modeling: Of Monoclonal Antibodies

  2009cited by this paper
• Dynamics of target-mediated drug disposition.

  2009cited by this paper
• Pharmacokinetic allometric scaling of antibodies: application to the first-in-human dose estimation.

  2009cited by this paper
• Target-mediated drug disposition model: relationships with indirect response models and application to population PK–PD analysis

  2009cited by this paper
• Pharmacokinetic and Pharmacodynamic Modeling of Pegylated Thrombopoietin Mimetic Peptide (PEG‐TPOm) After Single Intravenous Dose Administration in Healthy Subjects

  2009cited by this paper
• Use of pharmacokinetic/ pharmacodynamic modelling for starting dose selection in first-in-human trials of high-risk biologics.

  2009cited by this paper
• Population Pharmacokinetic Modelling of Filgrastim in Healthy Adults following Intravenous and Subcutaneous Administrations

  2009cited by this paper
• Integrated Cellular Bone Homeostasis Model for Denosumab Pharmacodynamics in Multiple Myeloma Patients

  2008cited by this paper
• Approximations of the target-mediated drug disposition model and identifiability of model parameters

  2008cited by this paper
• Pharmacokinetics and pharmacodynamics of erythropoietin receptor in healthy volunteers

  2008cited by this paper
• Partial derivative—Based sensitivity analysis of models describing target-mediated drug disposition

  2007cited by this paper
• Target-mediated pharmacokinetic and pharmacodynamic model of recombinant human erythropoietin (rHuEPO)

  2007cited by this paper
• The role of mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modelling in translational research of biologics.

  2007cited by this paper
• Population Pharmacokinetics Meta-Analysis of Recombinant Human Erythropoietin in Healthy Subjects

  2007cited by this paper
• Target-mediated drug disposition and dynamics.

  2006cited by this paper
• Pharmacokinetics/Pharmacodynamics of Nondepleting Anti-CD4 Monoclonal Antibody (TRX1) in Healthy Human Volunteers

  2006cited by this paper
• On the prediction of the human response: a recycled mechanistic pharmacokinetic/pharmacodynamic approach.

  2005cited by this paper
• Quasi-Equilibrium Pharmacokinetic Model for Drugs Exhibiting Target-Mediated Drug Disposition

  2005cited by this paper
• A Pharmacology Primer: Theory, Application and Methods

  2004cited by this paper
• Pharmacokinetic model of target-mediated disposition of thrombopoietin.

  2004cited by this paper
• Pharmacokinetics of Recombinant Human Leukemia Inhibitory Factor in Sheep

  2004cited by this paper
• Pharmacokinetic model of target-mediated disposition of thrombopoietin

  2004cited by this paper
• Application of pharmacokinetic-pharmacodynamic modeling to predict the kinetic and dynamic effects of anti-methotrexate antibodies in mice.

  2003cited by this paper
• Receptor-Mediated Pharmacokinetics and Pharmacodynamics of Interferon-β1a in Monkeys

  2003cited by this paper
• Simultaneous Modeling of Abciximab Plasma Concentrations and ex Vivo Pharmacodynamics in Patients Undergoing Coronary Angioplasty

  2003cited by this paper
• Receptor-Mediated Pharmacokinetic/Pharmacodynamic Model of Interferon-β 1a in Humans

  2002cited by this paper
• A target‐mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans

  2002cited by this paper
• General Pharmacokinetic Model for Drugs Exhibiting Target-Mediated Drug Disposition

  2001cited by this paper
• Pharmacologic target‐mediated drug disposition

  1994influential reference
• Receptor-Mediated Transport of Peptide Hormones and Its Importance in the Overall Hormone Disposition in the Body

  1989cited by this paper
• Effect of saturable binding on the pharmacokinetics of drugs: a simulation

  1980cited by this paper
• Effect of plasma protein and tissue binding on the time course of drug concentration in plasma

  1979cited by this paper
• Biopharmaceutics and Relevant Pharmacokinetics

  1971cited by this paper

• Refined target-mediated drug disposition modeling of the anti-tissue factor pathway inhibitor antibody MG1113 in cynomolgus monkeys and rabbits

  2026cites this paper
• Subcutaneous Administration of Antibody-drug Conjugates

  2026cites this paper
• Pharmacokinetics as a Biomarker

  2026cites this paper
• Immuno−oncological effects of aerobic exercise combined with anti−PD−L1 antibody blockade in a murine breast cancer model

  2026cites this paper
• Population Pharmacokinetic Model of Pegbing in Healthy Subjects and Chronic Hepatitis B Patients

  2025cites this paper
• Population pharmacokinetics/pharmacodynamics analysis confirming biosimilarity of SB16 to reference denosumab

  2025cites this paper
• A Tutorial on the Development of a Physiologically Inspired PKRO Model for Monoclonal Antibodies

  2025cites this paper
• Advanced cytokine-based immunotherapies: targeted cis-delivery strategies for enhanced anti-tumor efficacy and reduced toxicity

  2025cites this paper
• Enhancing viral dynamics modeling: reliable initial estimation and validity conditions for quasi-steady state approximation (QSSA)

  2025cites this paper
• Pharmacometric modeling with the zero-order hold

  2025cites this paper
• Model‐Informed Optimal Dosing of Anti‐CD47 Antibody Using Target‐Mediated Drug Disposition Model

  2025cites this paper
• Immunoglobulin G Receptors (FcγR), in Addition to Target-Antigen and Neonatal Fc Receptor (FcRn), Influence Rituximab Pharmacokinetics

  2025cites this paper
• Target‐Mediated Drug Disposition Revisited: Michaelis–Menten Approximations for Bivalent Drug Molecules

  2025cites this paper
• Dose-response characterization: A key to success in drug development

  2025cites this paper
• Characterization of free light chain impurity in a bispecific antibody

  2025cites this paper
• Target‐Mediated Drug Disposition (TMDD) Revisited: High Versus Low‐Affinity Approximations of the TMDD Model

  2025cites this paper
• Dose Optimization of rhIL‐7‐hyFc for Patients With Lymphopenia Using a Neonatal Fc Receptor‐Mediated Recycling‐Based and Target‐Mediated Drug Disposition Pharmacokinetic Model

  2025cites this paper
• An Integrative Mechanistic Model of Type 1 IFN‐Mediated Inflammation in Systemic Lupus Erythematosus

  2025cites this paper
• Factors Influencing Monoclonal Antibody Pharmacokinetics Across Varying Immune Perturbations

  2025cites this paper
• Breadth of Pharmacology Modeling: Fundamentals of Pharmacokinetics, Pharmacodynamics, and Mechanistic Modeling.

  2025cites this paper
• Accelerating Biologics PBPK Modelling with Automated Model Building: A Tutorial

  2025cites this paper
• Nondegradative Synthetic Molecular Glues Enter the Clinic

  2025cites this paper
• Safety, pharmacokinetics and population pharmacokinetic model of TQH2722, a novel IL-4Rα monoclonal antibody in healthy subjects: a phase I, first-in-human, single-dose and multiple-dose escalation study.

  2025cites this paper
• Quantifying antibody binding: techniques and therapeutic implications

  2025cites this paper
• Analysis and Simulation of Some Target-Mediated Drug Disposition Mathematical Models

  2025influential citation
• Stability and Hopf Bifurcation of a Target-Mediated Drug Disposition Model

  2025cites this paper
• Structure-Guided Elaboration of a Fragment-Like Hit into an Orally Efficacious Leukotriene A4 Hydrolase Inhibitor.

  2024cites this paper
• First‐in‐Human Study of BAT4406F, an ADCC‐Enhanced Fully Humanized Anti‐CD20 Monoclonal Antibody in Patients With Neuromyelitis Optica Spectrum Disorders

  2024cites this paper
• Model-informed drug discovery and development approaches to inform clinical trial design and regulatory decisions: A primer for the MENA region

  2024cites this paper
• Local depletion of large molecule drugs due to target binding in tissue interstitial space

  2024cites this paper
• A model‐based approach using GSK3772847, an anti‐interleukin‐33 receptor monoclonal antibody, as a showcase to predict SC administration PK and free target dynamics based on PK and total target measurements after IV administration

  2024cites this paper
• Population pharmacokinetic/target engagement modelling of tozorakimab in healthy volunteers and patients with chronic obstructive pulmonary disease

  2024cites this paper
• A Population Pharmacokinetic Model of Tocilizumab in Kidney Transplant Patients Treated for Chronic Active Antibody-Mediated Rejection: Comparison of Plasma Exposure Between Intravenous and Subcutaneous Administration Schemes

  2024cites this paper
• Note on importance of correct stoichiometric assumptions for modeling of monoclonal antibodies

  2024cites this paper
• Validity conditions of approximations for a target-mediated drug disposition model: A novel first-order approximation and its comparison to other approximations

  2024cites this paper
• A mechanism-based pathway toward administering highly active N-phage cocktails

  2023cites this paper
• Clinical and research updates on the VISTA immune checkpoint: immuno-oncology themes and highlights

  2023cites this paper
• Advances in Pharmacokinetic Modelling and Computational Approaches for Nanoparticles in Drug Delivery Systems.

  2023cites this paper
• Preclinical development of 1B7/CD3, a novel anti-TSLPR bispecific antibody that targets CRLF2-rearranged Ph-like B-ALL

  2023cites this paper
• Prediction of relative change in free nerve growth factor following subcutaneous administration of tanezumab, a novel monoclonal antibody to nerve growth factor

  2023cites this paper
• Relationship Between Cetuximab Target-Mediated Pharmacokinetics and Progression-Free Survival in Metastatic Colorectal Cancer Patients

  2023cites this paper
• A 20-Year Research Overview: Quantitative Prediction of Hepatic Clearance Using the In Vitro-In Vivo Extrapolation Approach Based on Physiologically Based Pharmacokinetic Modeling and Extended Clearance Concept

  2023cites this paper
• Physiologically-Based Toxicokinetic Model of Botulinum Neurotoxin Biodistribution in Mice and Rats

  2023cites this paper
• Sabatolimab (MBG453) model‐informed drug development for dose selection in patients with myelodysplastic syndrome/acute myeloid leukemia and solid tumors

  2023cites this paper
• Pharmacokinetic/pharmacodynamic model of a methionine starvation based anti-cancer drug

  2023cites this paper
• Improving the efficacy of plant-made anti-HIV monoclonal antibodies for clinical use

  2023cites this paper
• Pharmacokinetics and tolerability of prefilled syringe and auto-injector presentations of MSB11456: results of a randomized, single-dose study in healthy adults

  2023cites this paper
• Best Practices in mAb and Soluble Target Assay Selection for Quantitative Modelling and Qualitative Interpretation

  2023cites this paper
• A mechanistic PK/PD model to enable dose selection of the potent anti‐tryptase antibody (MTPS9579A) in patients with moderate‐to‐severe asthma

  2023cites this paper
• The quest for balance between capturing data and model complexity: A quantitative clinical pharmacology approach applied to monoclonal antibodies

  2023cites this paper
• Pharmacokinetics of a proposed tocilizumab biosimilar (MSB11456) versus US-licensed tocilizumab: results of a randomized, double-blind, single-intravenous dose study in healthy adults

  2023cites this paper
• Antibody drug clearance: an underexplored marker of outcomes with checkpoint inhibitors.

  2023cites this paper
• Nonlinear Population Pharmacokinetics of Anifrolumab in Healthy Volunteers and Patients With Systemic Lupus Erythematosus

  2022cites this paper
• Population Pharmacokinetic–B Cell Modeling for Ofatumumab in Patients with Relapsing Multiple Sclerosis

  2022cites this paper
• Characterizing the Pharmacokinetics and Biodistribution of Therapeutic Proteins: An Industry White Paper

  2022cites this paper
• Impact of enzyme turnover on the dynamics of the Michaelis-Menten model.

  2022cites this paper
• Recent advances in the translation of drug metabolism and pharmacokinetics science for drug discovery and development

  2022cites this paper
• Special Section on Pharmacokinetics and ADME of Biological Therapeutics — Minireview Characterizing the Pharmacokinetics and Biodistribution of Therapeutic Proteins: An Industry White Paper

  2022cites this paper
• Early Feasibility Assessment: A Method for Accurately Predicting Biotherapeutic Dosing to Inform Early Drug Discovery Decisions

  2022cites this paper
• System Analysis of Target-Mediated Drug Disposition (TMDD) Models

  2022cites this paper
• Bayesian Nonlinear Models for Repeated Measurement Data: An Overview, Implementation, and Applications

  2022cites this paper
• Berkeley Madonna Version 10–A simulation package for solving mathematical models

  2022cites this paper
• Review of the Existing Translational Pharmacokinetics Modeling Approaches Specific to Monoclonal Antibodies (mAbs) to Support the First-In-Human (FIH) Dose Selection

  2022cites this paper
• Application of physiologically based pharmacokinetic models for therapeutic proteins and other novel modalities

  2022cites this paper
• Interpretation of Clinical Efficacy of Biologics in Chronic Rhinosinusitis With Nasal Polyps via Understanding the Local and Systemic Pathomechanisms

  2022cites this paper
• Biological Therapy in Refractory Chronic Rhinosinusitis with Nasal Polyp

  2022cites this paper
• Assessment of Strategies for Safe Drug Discontinuation and Transition of Denosumab Treatment in PMO—Insights From a Mechanistic PK/PD Model of Bone Turnover

  2022cites this paper
• Infliximab Efficacy May Be Linked to Full TNF-α Blockade in Peripheral Compartment—A Double Central-Peripheral Target-Mediated Drug Disposition (TMDD) Model

  2021cites this paper
• Dynamical Modeling of Different Drug Modalities in Drug Research

  2021cites this paper
• Therapeutic antibody development—Remington chapter

  2021cites this paper
• Target‐mediated drug disposition modeling of an anti‐TFPI antibody (MG1113) in cynomolgus monkeys to predict human pharmacokinetics and pharmacodynamics

  2021cites this paper
• Pivotal Dose of Pembrolizumab: A Dose‐Finding Strategy for Immuno‐Oncology

  2021cites this paper
• A Phase I Clinical Study Comparing the Tolerance, Immunogenicity, and Pharmacokinetics of Proposed Biosimilar BAT1806 and Reference Tocilizumab in Healthy Chinese Men

  2021cites this paper
• Physiologically Based Pharmacokinetic (PBPK) Modeling of RNAi Therapeutics: Opportunities and Challenges.

  2021cites this paper
• Safety and pharmacokinetics of a new biosimilar trastuzumab (HL02): a Phase I bioequivalence study in healthy Chinese men

  2021cites this paper
• Real world use of biologic drug levels and anti-drug antibodies in patients with psoriasis – does therapeutic drug monitoring have a place in routine clinical practice?

  2021cites this paper
• Modeling Pharmacokinetics and Pharmacodynamics of Therapeutic Antibodies: Progress, Challenges, and Future Directions

  2021cites this paper
• Drug distribution in lung tissue

  2021cites this paper
• Frontiers in mathematical modelling of the lipid metabolism under normal conditions and its alterations in heart diseases

  2021cites this paper
• An Extended Model Including Target Turnover, Ligand-Target Complex Kinetics, and Binding Properties to Describe Drug-Receptor Interactions.

  2021cites this paper
• Assessment of romosozumab efficacy in the treatment of postmenopausal osteoporosis: results from a mechanistic PK-PD mechanostat model of bone remodeling.

  2020cites this paper
• Dose Correction for a Michaelis–Menten Approximation of a Target-Mediated Drug Disposition Model with a Multiple Intravenous Dosing Regimens

  2020cites this paper
• Global dynamics of target-mediated drug disposition models and their solutions by nonstandard finite difference method

  2020cites this paper
• Pharmacokinetics and Pharmacodynamics of Garetosmab ( Anti-Activin A ) : Results From a First-inHuman Phase 1 Study

  2020cites this paper
• Development of a Pharmacokinetic Model Describing Neonatal Fc Receptor‐Mediated Recycling of HL2351, a Novel Hybrid Fc‐Fused Interleukin‐1 Receptor Antagonist, to Optimize Dosage Regimen

  2020cites this paper
• Population pharmacokinetics and pharmacodynamics of a novel vascular adhesion protein-1 inhibitor using a multiple-target mediated drug disposition model

  2020cites this paper
• Hemopexin as an Inhibitor of Hemolysis-Induced Complement Activation

  2020cites this paper
• Pharmacokinetics and Pharmacodynamics of Garetosmab (Anti‐Activin A): Results From a First‐in‐Human Phase 1 Study

  2020cites this paper
• Explainig interpatient variability in adalimumab pharmacokinetics in patients with Crohn’s disease

  2020cites this paper
• Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Dupilumab in Healthy Adult Subjects

  2020cites this paper
• Simultaneous Target-Mediated Drug Disposition Model for Two Small-Molecule Compounds Competing for Their Pharmacological Target: Soluble Epoxide Hydrolase

  2020cites this paper
• Safety, pharmacokinetics and pharmacodynamics of branebrutinib (BMS‐986195), a covalent, irreversible inhibitor of Bruton's tyrosine kinase: Randomised phase I, placebo‐controlled trial in healthy participants

  2020cites this paper
• Modeling and Simulation of the Pharmacokinetics and Target Engagement of an Antagonist Monoclonal Antibody to Interferon‐γ–Induced Protein 10, BMS‐986184, in Healthy Participants to Guide Therapeutic Dosing

  2020cites this paper
• Pharmacokinetics and pharmacodynamic effect of crenezumab on plasma and cerebrospinal fluid beta-amyloid in patients with mild-to-moderate Alzheimer’s disease

  2020cites this paper
• Effects of long-term treatment of denosumab on bone mineral density: insights from an in-silico model of bone mineralization.

  2019cites this paper
• Development of a Computational Modelling Platform for Patient-specific Treatment of Osteoporosis

  2019cites this paper
• Concept of Pharmacologic Target‐Mediated Drug Disposition in Large‐Molecule and Small‐Molecule Compounds

  2019cites this paper
• Mathematical modeling of the glucagon challenge test

  2019cites this paper
• Comparing Model Performance in Characterizing the PK/PD of the Anti‐Myostatin Antibody Domagrozumab

  2019cites this paper
• A multi-scale model for low-density lipoprotein cholesterol (LDL-C) regulation in the human body: Application to quantitative systems pharmacology

  2019cites this paper